144 related articles for article (PubMed ID: 38679969)
21. Homologous versus Heterologous prime-boost COVID-19 Vaccination in autologous hematopoietic stem cell transplantation recipients: a blinded randomized controlled trial.
Sharifi Aliabadi L; Karami M; Barkhordar M; Hashemi Nazari SS; Kavousi A; Ahmadvand M; Vaezi M
Front Immunol; 2023; 14():1237916. PubMed ID: 37593732
[TBL] [Abstract][Full Text] [Related]
22. COVID-19 vaccines mix-and-match: The concept, the efficacy and the doubts.
Rashedi R; Samieefar N; Masoumi N; Mohseni S; Rezaei N
J Med Virol; 2022 Apr; 94(4):1294-1299. PubMed ID: 34796525
[TBL] [Abstract][Full Text] [Related]
23. Predictors of neutralizing antibody response to BNT162b2 vaccination in allogeneic hematopoietic stem cell transplant recipients.
Canti L; Humblet-Baron S; Desombere I; Neumann J; Pannus P; Heyndrickx L; Henry A; Servais S; Willems E; Ehx G; Goriely S; Seidel L; Michiels J; Willems B; Liston A; Ariën KK; Beguin Y; Goossens ME; Marchant A; Baron F
J Hematol Oncol; 2021 Oct; 14(1):174. PubMed ID: 34689821
[TBL] [Abstract][Full Text] [Related]
24. Randomized Trial of a Third Dose of mRNA-1273 Vaccine in Transplant Recipients.
Hall VG; Ferreira VH; Ku T; Ierullo M; Majchrzak-Kita B; Chaparro C; Selzner N; Schiff J; McDonald M; Tomlinson G; Kulasingam V; Kumar D; Humar A
N Engl J Med; 2021 Sep; 385(13):1244-1246. PubMed ID: 34379917
[No Abstract] [Full Text] [Related]
25. B Cell Aplasia Is the Most Powerful Predictive Marker for Poor Humoral Response after BNT162b2 mRNA SARS-CoV-2 Vaccination in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation.
Jullien M; Le Bourgeois A; Coste-Burel M; Peterlin P; Garnier A; Rimbert M; Imbert BM; Le Gouill S; Moreau P; Mahe B; Dubruille V; Blin N; Lok A; Touzeau C; Gastinne T; Tessoulin B; Vantyghem S; Béné MC; Guillaume T; Chevallier P
Transplant Cell Ther; 2022 May; 28(5):279.e1-279.e4. PubMed ID: 35218998
[TBL] [Abstract][Full Text] [Related]
26. Third BNT162b2 Vaccination Neutralization of SARS-CoV-2 Omicron Infection.
Nemet I; Kliker L; Lustig Y; Zuckerman N; Erster O; Cohen C; Kreiss Y; Alroy-Preis S; Regev-Yochay G; Mendelson E; Mandelboim M
N Engl J Med; 2022 Feb; 386(5):492-494. PubMed ID: 34965337
[No Abstract] [Full Text] [Related]
27. Non-COVID-19 hospitalisation as a negative control outcome in COVID-19 vaccine effectiveness studies - Authors' reply.
Hansen CH; Moustsen-Helms IR; Rasmussen M; Søborg B; Ullum H; Valentiner-Branth P
Lancet Infect Dis; 2024 May; 24(5):e276. PubMed ID: 38402888
[No Abstract] [Full Text] [Related]
28. Strong SARS-CoV-2 T-Cell Responses after One or Two COVID-19 Vaccine Boosters in Allogeneic Hematopoietic Stem Cell Recipients.
Clémenceau B; Le Bourgeois A; Guillaume T; Coste-Burel M; Peterlin P; Garnier A; Jullien M; Ollier J; Grain A; Béné MC; Chevallier P
Cells; 2022 Sep; 11(19):. PubMed ID: 36230971
[TBL] [Abstract][Full Text] [Related]
29. SARS-CoV-2 vaccine antibody response and breakthrough infections in transplant recipients.
Vanlerberghe B; Vrij C; Bogaerts K; Vermeersch P; Lagrou K; Molenberghs G; Rega F; Ceulemans LJ; van Raemdonck D; Jochmans I; Monbaliu D; Pirenne J; Vanuytsel T; Gillard P; Schoemans H; Cleemput JV; Kuypers D; Vos R; Nevens F; Verbeek J
J Med Virol; 2023 Apr; 95(4):e28736. PubMed ID: 37185854
[TBL] [Abstract][Full Text] [Related]
30. mRNA-1273 SARS-CoV-2 vaccine safety and COVID-19 risk perception in recently transplanted allogeneic hematopoietic stem cell transplant recipients.
Albiol N; Aso O; Gómez-Pérez L; Triquell M; Roch N; Lázaro E; Esquirol A; González I; López-Contreras J; Sierra J; Martino R; García-Cadenas I
Support Care Cancer; 2022 Dec; 30(12):9687-9690. PubMed ID: 36169731
[TBL] [Abstract][Full Text] [Related]
31. Risk factors and characteristics influencing humoral response to COVID-19 vaccination in patients after allogeneic stem cell transplantation.
Hütter-Krönke ML; Neagoie A; Blau IW; Wais V; Vuong L; Gantner A; Ahn J; Penack O; Schnell J; Nogai KA; Eberspächer B; Saadati M; Benner A; Bullinger L; Döhner H; Bunjes D; Sala E
Front Immunol; 2023; 14():1174289. PubMed ID: 37207199
[TBL] [Abstract][Full Text] [Related]
32. Antibody response to a third SARS-CoV-2 vaccine dose in recipients of an allogeneic haematopoietic cell transplantation.
Bankova AK; Pasin C; Huang A; Cicin-Sain C; Epp S; Audige A; Mueller NJ; Nilsson J; Vilinovszki O; Nair G; Wolfensberger N; Hockl P; Schanz U; Trkola A; Kouyos R; Hasse B; Zinkernagel AS; Manz MG; Abela IA; Müller AMS
Br J Haematol; 2023 Apr; 201(1):58-63. PubMed ID: 36382698
[TBL] [Abstract][Full Text] [Related]
33. Decoupling of omicron variant infections and severe COVID-19.
Madhi SA; Ihekweazu C; Rees H; Pollard AJ
Lancet; 2022 Mar; 399(10329):1047-1048. PubMed ID: 35189080
[No Abstract] [Full Text] [Related]
34. Dynamic IgG seropositivity after rollout of CoronaVac and BNT162b2 COVID-19 vaccines in Chile: a sentinel surveillance study.
Sauré D; O'Ryan M; Torres JP; Zuniga M; Santelices E; Basso LJ
Lancet Infect Dis; 2022 Jan; 22(1):56-63. PubMed ID: 34509185
[TBL] [Abstract][Full Text] [Related]
35. SARS-CoV-2 Messenger RNA Vaccine Immunogenicity in Solid Organ Transplant Recipients With Prior COVID-19.
Boyarsky BJ; Barbur I; Chiang TP; Ou MT; Greenberg RS; Teles AT; Krach MR; López JI; Garonzik-Wang JM; Avery RK; Massie AB; Segev DL; Werbel WA
Transplantation; 2021 Nov; 105(11):e270-e271. PubMed ID: 34284420
[No Abstract] [Full Text] [Related]
36. Impact of a third dose of anti-SARS-CoV-2 vaccine in hematopoietic cell transplant recipients: A Japanese multicenter observational study.
Mori Y; Uchida N; Wake A; Miyawaki K; Eto T; Nakamura T; Iwasaki H; Ito Y; Tanimoto K; Katayama Y; Imamura Y; Takahashi T; Fujisaki T; Kamimura T; Choi I; Ishitsuka K; Yoshimoto G; Ogawa R; Sugita J; Takamatsu Y; Tanimoto K; Hidaka T; Miyamoto T; Akashi K; Nagafuji K
Vaccine; 2023 Nov; 41(47):6899-6903. PubMed ID: 37866994
[TBL] [Abstract][Full Text] [Related]
37. Antibody Response to SARS-CoV-2 Vaccination in Patients following Allogeneic Hematopoietic Cell Transplantation.
Huang A; Cicin-Sain C; Pasin C; Epp S; Audigé A; Müller NJ; Nilsson J; Bankova A; Wolfensberger N; Vilinovszki O; Nair G; Hockl P; Schanz U; Kouyos RD; Hasse B; Zinkernagel AS; Trkola A; Manz MG; Abela IA; Müller AMS
Transplant Cell Ther; 2022 Apr; 28(4):214.e1-214.e11. PubMed ID: 35092892
[TBL] [Abstract][Full Text] [Related]
38. Antibody response after 2 and 3 doses of SARS-CoV-2 mRNA vaccine in allogeneic hematopoietic cell transplant recipients.
Maillard A; Redjoul R; Klemencie M; Labussière Wallet H; Le Bourgeois A; D'Aveni M; Huynh A; Berceanu A; Marchand T; Chantepie S; Botella Garcia C; Loschi M; Joris M; Castilla-Llorente C; Thiebaut-Bertrand A; François S; Leclerc M; Chevallier P; Nguyen S
Blood; 2022 Jan; 139(1):134-137. PubMed ID: 34818411
[No Abstract] [Full Text] [Related]
39. Oldest Adults Need 2 mRNA Vaccine Doses to Neutralize SARS-CoV-2.
Abbasi J
JAMA; 2021 Aug; 326(6):473. PubMed ID: 34374737
[No Abstract] [Full Text] [Related]
40. The mRNA COVID-19 vaccine in patients with cancer receiving checkpoint inhibitor therapy: what we know and what we don't.
Malek AE; Cornejo PP; Daoud N; Alam M
Immunotherapy; 2022 Feb; 14(2):91-94. PubMed ID: 34747190
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
